Back

Prognostic Gene Signature for lung adenocarcinoma with a Higher Risk for Treatment Failure and Accelerated cell cycle and cell proliferation Pathway Activity

Li, Z.; Li, B.; Wei, S.; Li, X.; Li, Z.; Meng, Y.-q.; Zhai, K.-R.

2023-05-19 cancer biology
10.1101/2023.05.19.540490 bioRxiv
Show abstract

Lung cancer is the most common of malignant cancers which represents poor prognosis and high invasive. However, the reliable prognosis genes signature and the differential between the genetic and epigenetic are remain unclear. Here, we confirmed 78 genes of signature A to construct a model to predicted the prognosis and the activity of tumorigenesis-related pathways. The score based on the 78 genes expression is high correlation with the cell cycle and cell proliferation activity. Based on the median of score, the lung adenocarcinoma patients were divided into two cohorts which presents different prognosis, tumorigenesis-related pathways activity. The high score group was enriched in the E2F target, mtorc1 signaling and MYC targets. The low score group can be identified as better prognosis subtype. Also, we used the GDSC data to predicted the PIM inhibitor (AZD1208) as the effective compounds for high score group patients, which is supported by a higher PIM1 and PIM2 expression in the score group. An integrative analysis of multi-omics data identified ECT2 as key nodes in a regulatory network related to the prognostic phenotype. In conclusion, our data identified a molecular classifier for the different score groups patients, and the high score group patients might benefit from treatment with PIM inhibitor.

Matching journals

The top 12 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.